Related Experiment Video

Updated: Jul 18, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Glycoprotein IIb/IIIa inhibitor-induced thrombocytopenia: diagnosis and treatment

S M Said1, J Hahn, E Schleyer

  • 1Carl-von-Basedow-Klinikum Merseburg, Medizinische Klinik I, Germany. s.said@klinikum-merseburg.de

Clinical Research in Cardiology : Official Journal of the German Cardiac Society
|December 6, 2006
PubMed

Insights

Glycoprotein (GP) IIb/IIIa inhibitors can cause thrombocytopenia, a low platelet count, which may lead to serious bleeding and adverse outcomes. Early monitoring and discontinuation of these drugs can prevent complications.

Area of Science:

  • Cardiology
  • Hematology
  • Pharmacology

Background:

  • Glycoprotein (GP) IIb/IIIa inhibitors are crucial in managing acute coronary syndromes (ACS), particularly non-ST-elevation myocardial infarction (NSTEMI) and percutaneous coronary intervention (PCI).
  • These agents function by inhibiting fibrinogen binding and subsequent platelet aggregation at sites of coronary plaque rupture.
  • Thrombocytopenia, a decrease in platelet count, is a recognized complication of GP IIb/IIIa inhibitor therapy.

Purpose of the Study:

  • To review the diagnosis and management of GP IIb/IIIa inhibitor-induced thrombocytopenia.
  • To differentiate this condition from heparin-induced thrombocytopenia and laboratory-related pseudothrombocytopenia.
  • To highlight the clinical significance and risk factors associated with GP IIb/IIIa inhibitor-induced thrombocytopenia.

Main Methods:

  • Review of literature on GP IIb/IIIa inhibitors and associated thrombocytopenia.
  • Analysis of risk factors, clinical presentation, and outcomes of thrombocytopenia.
  • Discussion of diagnostic criteria and differential diagnoses.
  • Emphasis on monitoring strategies and treatment implications.

Main Results:

  • GP IIb/IIIa inhibitor-induced thrombocytopenia, while often benign, can lead to severe bleeding and unfavorable patient outcomes, including death or myocardial infarction.
  • Independent risk factors for developing thrombocytopenia include advanced age (>65 years), low body mass index (BMI), and low baseline platelet count (<180,000/microl).
  • Bleeding risk is exacerbated by both the reduced platelet count and impaired function of remaining platelets.

Conclusions:

  • Close monitoring of platelet counts during GP IIb/IIIa antagonist treatment is essential, with specific attention to counts at 2, 6, 12, and 24 hours post-initiation.
  • Early discontinuation of GP IIb/IIIa inhibitors is key to avoiding serious side effects.
  • Distinguishing GP IIb/IIIa inhibitor-induced thrombocytopenia from other causes is critical for appropriate management.

More Related Videos

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel07:26

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel

Published on: June 29, 2015

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...